Date: 2nd November, 2021

To The Manager Dept of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai-400001 Scrip Code: 511 509

Dear Sir/Madam,


Sub: Outcome of Board Meeting-Reg.

Ref: Regulation 30 & other applicable Regulations of SEBI (LODR) Regulations, 2015.

We wish to inform you that the Board of Directors of the Company, in their just concluded meeting, inter-alia, transacted the following items of business:

- Approved the Un-Audited Standalone Financial Results for the Second Quarter and half year ended 30th September, 2021 as recommended by the Audit committee and Reviewed by the Statutory Auditors.
- Approved the Un-Audited Consolidated Financial Results for the Second Quarter and half year ended 30th September, 2021 as recommended by the Audit committee and Reviewed by the Statutory Auditors.
- Approved the resignation of Mr. K.T.V. Kaladhar (DIN: 08450361), to the office of Director & CFO of the Company with effect from Wednesday, i.e. 3rd November, 2021 due to personal reasons.

The Board of Directors has placed on record its sincere appreciation for Mr. K.T.V. Kaladhar for his valuable services, guidance and contribution to the Company during his tenure as a member of the Board and wishes him very best in his future endeavors.



Registered Office : # 8-2-672/5&6, Ilyas Mohanmmed Khan Estate, 3rd Floor, Road No-1, Banjarahills, Hyderabad, India -500034. Address of Preclinical Research Facility : Sy.No:349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email : investors@vivobio.com, Phone : 040-23313288, Website : www.vivobio.com, CIN : L65993TG1987PLC007163. 4. Based on the recommendation of the Nomination & Remuneration Committee the Board of Directors have appointed Mr. K. Sri Kalyan (DIN: 03137506) as an Additional Director (Whole Time Director) of the Company for a period of 5 (five) years with effect from Wednesday, i.e. 3rd November, 2021 subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting.

Further, in accordance with the circular dated 20th June, 2018, issued by the Stock Exchanges, he is not debarred from holding office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

- Based on the recommendation of the Nomination & Remuneration Committee the Audit Committee and Board of Directors have approved the appointment of Mr. K. Sri Kalyan as Chief Financial Officer of the Company (CFO) with effect from Wednesday, i.e. 3rd November, 2021.
- 6. Change in Authorisation under regulation 30 (5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the contact details of the Key Managerial Personnel ("KMP") who have been severally authorized by Board of Directors of the Company with effect from Wednesday i.e. 3rd November, 2021, for the purpose of determining materiality of an event or information to the Stock Exchanges from time to time under the said regulation is as follows:

Name of the KMP	Designation	Contact Details
Mr. M. Kalyan Ram	Whole Time Director	Email: investors@vivobio.com
		Phone: 040-2331 3288
Mr. K. Sri Kalyan	Whole Time Director &	Email: investors@vivobio.com
	CFO	Phone: 040-2331 3288
Mr. A. Karthik	Company Secretary &	Email: Karthik@vivobio.com
	Compliance Officer	Phone:040-2331 3288



The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD|CMD|4|1015 dated 09th September 2015; including the brief profile of the above Directors is enclosed in Annexure-A to this letter.

A copy of this letter is being hosted on the Company's website at www.vivobio.com. .

The meeting commenced at 6.45 P.M and concluded at 7.30 P.M.

This is for your information and records.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

Thik

A.Karthik Company Secretary

CA HYDERABAD

Annexure-A

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. K. Sri Kalyan (DIN: 03137506) as an Additional Whole Time Director & CFO of the Company.
2.	Date of appointment/ cessation (as applicable) & term of appointment;	Appointment with effect from 3 rd November, 2021 for a period of 5 years subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting.
3.	Brief profile (in case of appointment);	He is a Post Graduate from prestigious SP Jain Center of Management and brings in a total of 20 years of rich and diverse experience to the board. He started his career with Tecumseh Products Company and worked on launching various new products in Indian market. Subsequently, he worked in Virinchi Health care in Projects & Operations division for their flag ship multi-specialty 600 bed hospital. He brings to Vivo Bio, rich and diverse experience cutting across Manufacturing, Statistical Quality Control, Project & Operations Management, Bio Tech - Test Facility Management of Health Care.
4.	Qualifications	B.E (Osmania University) & MBA (SP Jain Center of Management)
5.	Disclosure of relationships between directors (in case of appointment of a director).	None of the Directors/ Key Managerial Personnel of the Company/ their relatives are in any way related or interested, financially or otherwise.

Details of Mr. K. Sri Kalyan



Registered Office : # 8-2-672/5&6, Ilyas Mohanmmed Khan Estate, 3rd Floor, Road No-1, Banjarahills, Hyderabad, India -500034. Address of Preclinical Research Facility : Sy.No:349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email : investors@vivobio.com, Phone : 040-23313288, Website : www.vivobio.com, CIN : L65993TG1987PLC007163.

Details of Mr. K.T.V. Kaladhar (DIN: 08450361)

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment,	Resignation of Mr. K.T.V. Kaladhar to
	resignation, removal, death or	the office of Director & CFO of the
	otherwise;	Company due to personal reasons.
2.	Date of appointment/cessation (as applicable) & term of appointment;	Wednesday, 3 rd November, 2021
3.	Brief profile (in case of appointment);	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

